- Generated total revenue of $781 million and global product
sales of $595 million, a 102% and 70% increase from the prior-year
period, respectively, while steadily improving operating
leverage
- Global sales of BRUKINSA totaled $358 million, a 130% increase
from the prior-year period, driven by launches in the U.S. and
Europe
- First TEVIMBRA approval in EU for 2L esophageal squamous cell
carcinoma (ESCC) accelerates global regulatory strategy for
cornerstone therapy
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global
biotechnology company, today reported financial results from the
third quarter of 2023 and business highlights.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231109537270/en/
“Our BeiGene team delivered another strong quarter across our
global product portfolio, driven by the ongoing successful launch
of BRUKINSA, where we continue to see rapid uptake across all
approved indications, including CLL,” said John V. Oyler, Chairman,
Co-Founder and CEO at BeiGene. “We are excited to have regained the
rights to TEVIMBRA worldwide, which is now approved in the EU and
under regulatory review in 10 additional markets. We are now better
positioned than ever before to execute on our global growth
strategy while steadily improving operating leverage with moderate
expense growth.”
Key Business and Pipeline
Highlights
- Generated global sales of BRUKINSA of $357.7 million, an
increase of 130% compared with the prior-year period, as global
launch momentum continues across multiple indications, including
chronic lymphocytic leukemia (CLL);
- Received a positive opinion from the European Committee for
Health and Medicinal Products (CHMP) of the European Medicines
Agency for BRUKINSA for the treatment of adult patients with
relapsed or refractory (R/R) follicular lymphoma (FL) who have
received at least two prior systematic treatments;
- Received positive guidance from the National Institute for
Health and Care Excellence for reimbursement of BRUKINSA on the
National Health Service in England and Wales for the treatment of
adult patients with R/R CLL;
- Regained global rights to the development, manufacture and
commercialization of TEVIMBRA, strengthening the Company’s global
portfolio in solid tumors;
- Announced European Commission (EC) approval of TEVIMBRA as
monotherapy for the treatment of adult patients with unresectable,
locally advanced or metastatic ESCC after prior platinum-based
chemotherapy; and
- Announced U.S. Food and Drug Administration (FDA) acceptance
for review of a Biologics License Application (BLA) for
tislelizumab as a first-line treatment for patients with
unresectable, recurrent, locally advanced, or metastatic ESCC with
a target action date in July 2024, under the Prescription Drug User
Fee Act (PDUFA).
Third Quarter 2023 Financial
Highlights
Total Revenue for the three months ended September 30,
2023, was $781.3 million, compared to $387.6 million in the same
period of 2022, representing 101.6% growth, driven by growth in
product revenue and the recognition of remaining deferred revenues
from the Novartis collaborations. Total revenue by geographic area
is presented as follows (amounts in thousands of U.S. dollars)
(1):
Three Months Ended
Nine Months Ended
September 30,
September 30,
2023
2022
2023
2022
$
$
$
$
United States- total revenue
398,229
133,431
815,059
347,180
Product revenue
270,084
108,104
632,391
264,373
Collaboration revenue
128,145
25,327
182,668
82,807
China- total revenue
287,935
233,077
831,399
636,241
Product revenue
284,981
233,077
825,809
636,241
Collaboration revenue
2,954
—
5,590
—
Europe- total revenue
85,583
17,995
153,273
46,634
Product revenue
30,664
5,200
76,487
9,205
Collaboration revenue
54,919
12,795
76,786
37,429
Rest of world- product revenue
9,561
3,125
24,639
5,771
Total Revenue
781,308
387,628
1,824,370
1,035,826
(1)
Net product revenues by geographic area are based upon the
location of the customer, and net collaboration revenue is recorded
in the jurisdiction in which the related income is expected to be
sourced from.
Product Revenue for the three months ended September 30,
2023, was $595.3 million, compared to $349.5 million in the same
period of 2022, representing 70.3% growth;
- Product sales increased $245.8 million in the third quarter of
2023 compared to the prior-year period, primarily due to increased
sales of our internally developed products, BRUKINSA and
tislelizumab, as well as increased sales of in-licensed products
from Amgen;
- U.S. sales of BRUKINSA totaled $270.1 million in the third
quarter of 2023, representing growth of 149.8% over the prior-year
period, as BRUKINSA continued to gain share across both TN and R/R
adult patients with CLL or small lymphocytic lymphoma (SLL) and
providers expanded adoption of all FDA-approved indications.
BRUKINSA sales in China totaled $47.4 million, representing growth
of 20.8% over the prior-year period, driven by increases in all
approved indications as the Company continues to increase market
value share as the Bruton’s tyrosine kinase inhibitor (BTKi) leader
in China;
- Sales of tislelizumab in China totaled $144.4 million in the
third quarter of 2023, representing growth of 12.6% compared to the
prior-year period. Continued increase in new patient demand from
reimbursement of new indications and further expansion of our
salesforce efficiency and hospital listings continued to drive
increased market penetration and leading PD-1 inhibitor market
share for tislelizumab. Market share for tislelizumab continued to
grow, despite a market slowdown in China during the quarter.
Gross Margin as a percentage of global product revenue
for the third quarter of 2023 was 83.8%, compared to 78.1% in the
prior-year period. The gross margin percentage increased primarily
due to proportionally higher sales mix of global BRUKINSA compared
to other products in the portfolio and compared to lower-margin
sales of in-licensed products, as well as lower costs per unit for
tislelizumab due to increased volume.
Operating Expenses for the three months ended September
30, 2023, were $819.0 million, compared to $749.4 million in the
same period of 2022, representing 9.3% growth, primarily due to
increased internal costs for research and development and sales and
marketing costs in the U.S. and Europe, compared to the prior-year
period. The Company expects product revenue growth to continue to
meaningfully outpace operating expense growth, generating continued
operating leverage.
Net Income for the quarter ended September 30, 2023, was
$215.4 million compared to net loss of $557.6 million in the same
period of 2022. The improvement in net income compared to the prior
year period was primarily attributable to reduced operating losses
and the non-operating gain of $362.9 million related to the BMS
arbitration settlement. Operating loss improved $304.4 million
compared to the prior-year period, as our product revenue growth
and management of expenses is driving increased operating leverage.
In addition, the reacquisition of the full global commercial rights
to ociperlimab and TEVIMBRA resulted in the recognition of the
remaining deferred collaboration revenue, which increased our total
revenue.
For the quarter ended September 30, 2023, basic and diluted
earnings per share were $0.16 and $0.15, respectively, and basic
and diluted earnings per American Depositary Share (ADS) were $2.06
and $2.01, respectively. For the quarter ended September 30, 2022,
net loss per share was $0.41 per share, and $5.39 per ADS.
Cash, Cash Equivalents, Restricted Cash, and Short-Term
Investments were $3.2 billion as of September 30, 2023, and
$4.5 billion as of December 31, 2022.
Cash used in operations for the quarter ended September 30, 2023
totaled $78.2 million compared to $561.9 million in the prior-year
period, driven by improved operating leverage.
For further details on BeiGene’s Third Quarter 2023 Financial
Statements, please see BeiGene’s Quarterly Report on Form 10-Q for
the third quarter of 2023 filed with the U.S. Securities and
Exchange Commission.
Regulatory Progress and Development
Programs
Category
Asset
Recent Milestones
Approvals/ Regulatory Updates
BRUKINSA
- Received approval of an updated label in the EU and UK for
superior progression-free survival (PFS) versus ibrutinib for the
treatment of R/R CLL based on results from the Phase 3 ALPINE
trial
- Received a positive CHMP opinion recommending approval in
combination with obinutuzumab for the treatment of adult patients
with R/R FL who have received at least two prior lines of systemic
therapy
- Received regulatory approvals in 13 markets for the treatment
of TN and R/R CLL
- Received Swissmedic approval for the treatment of R/R CLL
- Received first approval in Malaysia for the treatment of R/R
Waldenstr�m’s macroglobulinemia (WM)
- Received U.S. FDA approval of BeiGene Suzhou as an alternative
drug product manufacturing site
TEVIMBRA
- Received EC approval as monotherapy for the treatment of adult
patients with unresectable, locally advanced or metastatic ESCC
after prior platinum-based chemotherapy
BAITUOWEI® (Goserelin Microspheres for
Injection)
- In partnership with Luye Pharma, received China National
Medicinal Products Administration (NMPA) approval for the treatment
of breast cancer in premenopausal and perimenopausal women eligible
for hormone therapy
Regulatory Submissions
Tislelizumab
- Received U.S. FDA acceptance of BLA submission for the
treatment of first-line ESCC patients in combination with
chemotherapy, with a target PDUFA action date in July 2024
- Received NMPA acceptance of a supplemental Biologics License
Application (sBLA) submission as a combination therapy for the
treatment of first-line gastric cancer patients regardless of
PD-(L)1 expression
- Received NMPA acceptance of an sBLA for the treatment of
first-line extensive-stage small-cell lung cancer (ES-SCLC)
Clinical Activities
Tislelizumab
- Announced positive event-free survival (EFS) readout from the
Phase 3 RATIONALE 315 trial comparing neoadjuvant treatment or
placebo plus platinum-based chemotherapy followed by adjuvant
treatment or placebo in resectable stage II or IIIA non-small cell
lung cancer (NSCLC)
Sonrotoclax
(BGB-11417)
- Initiated global potentially registration enabling pivotal
trial in R/R WM
Early development
- Enrolled first patients in Phase 1 clinical trials for four New
Molecular Entities (NME), including BCL2i 2G*, CCR8 mAb, DGK and
HPK1 2G*
*Second generation
Anticipated Upcoming
Milestones
Category
Asset
Anticipated Milestone
Approvals/ Regulatory Updates
BRUKINSA
- Receive U.S. FDA approval of an sNDA for PFS superiority in R/R
CLL/SLL in the fourth quarter of 2023 based on results from the
Phase 3 ALPINE trial Receive U.S. FDA approval of an sNDA in
combination with obinutuzumab for the treatment of adult patients
with R/R FL who have received two prior lines of systemic therapy
in March 2024
Tislelizumab
- Receive U.S. FDA approval for the treatment of adult patients
with second-line ESCC in U.S. in 2023 or first half of 2024
- Receive U.S. FDA approval for the treatment of patients with
first- line unresectable, recurrent, locally advanced, or
metastatic ESCC with a target PDUFA action date in July 2024
- Receive EMA approval in combination with chemotherapy for the
first-line treatment of metastatic NSCLC and in the second line in
the first half of 2024
Regulatory Submissions
Tislelizumab
- Submit an sBLA with the U.S. FDA for the treatment of
first-line gastric cancer in 2023
- Submit an application for marketing and manufacturing approval
with the Japan PMDA for the treatment of first- and second-line
ESCC in the first half of 2024
- Submit an sBLA with the China NMPA for neoadjuvant treatment
plus platinum-based chemotherapy followed by adjuvant treatment of
adult patients with resectable Stage II or IIIA NSCLC in the first
half of 2024
- Submit an sBLA with the EMA for the treatment of adult patients
with first-line ESCC in the first quarter of 2024
Clinical Activities/Data
Readouts
BRUKINSA
- Announce additional follow-up data from the Phase 3 ALPINE
study versus IMBRUVICA in R/R CLL/SLL in the fourth quarter of
2023
Sonrotoclax
- Initiate global pivotal trial in combination with BRUKINSA in
first-line CLL in the fourth quarter of 2023
BTK CDAC (BGB-1663)
- Announce first data readouts from Phase 1 study in B-cell
malignancies at ASH in December 2023
Ociperlimab (Anti-TIGIT)
- Complete enrollment in the Phase 3 AdvanTIG-302 trial in
first-line NSCLC in the first quarter of 2024
Scientific Congress Updates
- Will present 24 accepted abstracts at the American Society of
Hematology (ASH) 2023 Annual Meeting in December, including
long-term follow-up data from the Phase 3 ALPINE trial of BRUKINSA
versus ibrutinib in adult patients with R/R CLL/SLL and clinical
data from a Phase 1/2 clinical trial of BRUKINSA in combination
with sonrotoclax in TN CLL;
- Presented 10 abstracts, including five oral presentations, at
the European Society for Medical Oncology (ESMO) 2023 Congress,
highlighted by:
- Final analysis results from the global, Phase 3 RATIONALE-305
study evaluating tislelizumab in combination with chemotherapy as a
first-line treatment of advanced gastric or gastroesophageal
junction adenocarcinoma (GC/GEJC); and
- Final analysis of pathological response to neoadjuvant
tislelizumab in combination with chemotherapy in patients with
resectable Stage II-IIIA non-small cell lung cancer (NSCLC) in
results from the Phase 3 RATIONALE-315 study;
- Presented final analysis data from the Phase 3 RATIONALE-312
trial for tislelizumab in combination with chemotherapy versus
chemotherapy alone for the first-line treatment of adult patients
with ES-SCLC at the 2023 World Conference on Lung Cancer.
Manufacturing Operations
- Entered final phase of construction at U.S. flagship
manufacturing and clinical R&D facility at the Princeton West
Innovation Campus in Hopewell, N.J. The property has more than 1
million square feet of total developable real estate, allowing for
future expansion; the site will be operational in summer 2024;
- Neared completion on construction of an ADC production facility
and additional biologics clinical production capabilities at our
state-of-the-art biologics facility in Guangzhou, China, which has
a current total capacity of 64,000 liters; and
- This month, will complete construction on our new small
molecule manufacturing campus in Suzhou, China. Phase 1 of
construction is expected to add more than 559,000 square feet and
expand production capacity to 600 million tablets/capsules per
year; once completed, qualified and approved, it is expected to
increase the current small molecule manufacturing capacity in China
by more than 5 times.
Corporate Developments
- Terminated a License and Collaboration Agreement with Zymeworks
for the clinical development and commercialization of its
investigational HER2-targeted bispecific antibody drug conjugate,
ZW49 (zanidatamab zovodotin), in Asia (excluding Japan), Australia
and New Zealand.
Financial
Summary
Select Condensed Consolidated Balance
Sheet Data (U.S. GAAP)
(Amounts in thousands of U.S. Dollars)
As of
September 30,
December 31,
2023
2022
(unaudited)
(audited)
Assets:
Cash, cash equivalents, restricted cash
and short-term investments
$
3,187,881
$
4,540,288
Accounts receivable, net
309,079
173,168
Inventories
316,929
282,346
Property, plant and equipment, net
1,178,038
845,946
Total assets
5,524,879
6,379,290
Liabilities and equity:
Accounts payable
341,857
294,781
Accrued expenses and other payables
505,824
467,352
Deferred revenue
300
255,887
R&D cost share liability
255,391
293,960
Debt
531,051
538,117
Total liabilities
1,761,645
1,995,935
Total shareholder’s equity
$
3,763,234
$
4,383,355
Condensed Consolidated Statements of
Operations (U.S. GAAP)
(Amounts in thousands of U.S. dollars,
except for shares, American Depositary Shares (ADSs), per share and
per ADS data)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2023
2022
2023
2022
(Unaudited)
(Unaudited)
Revenue:
Product revenue, net
$
595,290
$
349,506
$
1,559,326
$
915,590
Collaboration revenue
186,018
38,122
265,044
120,236
Total revenues
781,308
387,628
1,824,370
1,035,826
Expenses:
Cost of sales - products
96,309
76,543
274,088
212,953
Research and development
453,259
426,363
1,284,607
1,194,485
Selling, general and administrative
364,421
322,892
1,087,954
948,868
Amortization of intangible assets
1,287
187
1,662
563
Total expenses
915,276
825,985
2,648,311
2,356,869
Loss from operations
(133,968
)
(438,357
)
(823,941
)
(1,321,043
)
Interest income, net
26,649
12,759
57,735
34,261
Other income (expense), net
336,657
(125,640
)
291,142
(243,290
)
Income (loss) before income taxes
229,338
(551,238
)
(475,064
)
(1,530,072
)
Income tax expense
13,925
6,318
39,091
28,408
Net income (loss)
215,413
(557,556
)
(514,155
)
(1,558,480
)
Net income (loss) per share attributable
to BeiGene, Ltd.:
Basic
$
0.16
$
(0.41
)
$
(0.38
)
$
(1.16
)
Diluted
$
0.15
$
(0.41
)
$
(0.38
)
$
(1.16
)
Weighted-average shares outstanding:
Basic
1,360,716,279
1,345,303,747
1,358,392,470
1,337,976,853
Diluted
1,390,331,833
1,345,303,747
1,358,392,470
1,337,976,853
Net income (loss) per ADS attributable to
BeiGene, Ltd.:
Basic
$
2.06
$
(5.39
)
$
(4.92
)
$
(15.14
)
Diluted
$
2.01
$
(5.39
)
$
(4.92
)
$
(15.14
)
Weighted-average ADSs outstanding:
Basic
104,670,483
103,484,904
104,491,728
102,921,296
Diluted
106,948,603
103,484,904
104,491,728
102,921,296
About BeiGene
BeiGene is a global biotechnology company that is discovering
and developing innovative oncology treatments that are more
affordable and accessible to cancer patients worldwide. With a
broad portfolio, we are expediting development of our diverse
pipeline of novel therapeutics through our internal capabilities
and collaborations. We are committed to radically improving access
to medicines for far more patients who need them. Our growing
global team of more than 10,000 colleagues spans five continents,
with administrative offices in Basel, Beijing, and Cambridge, U.S.
To learn more about BeiGene, please visit www.beigene.com and
follow us on LinkedIn and X (formerly known as Twitter).
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
the ability of BeiGene to execute on its global growth strategy;
the advancement of and anticipated clinical activities, regulatory
submissions and approvals of BeiGene’s medicines and drug
candidates; BeiGene’s plans and the expected events and milestones
under the caption “Anticipated Upcoming Milestones”; the expected
capacities and completion dates for the Company's manufacturing
facilities under construction and the potential for such facilities
to increase manufacturing capabilities; and BeiGene's plans,
commitments, aspirations and goals under the caption “About
BeiGene”. Actual results may differ materially from those indicated
in the forward-looking statements as a result of various important
factors, including BeiGene's ability to demonstrate the efficacy
and safety of its drug candidates; the clinical results for its
drug candidates, which may not support further development or
marketing approval; actions of regulatory agencies, which may
affect the initiation, timing and progress of clinical trials and
marketing approval; BeiGene's ability to achieve commercial success
for its marketed medicines and drug candidates, if approved;
BeiGene's ability to obtain and maintain protection of intellectual
property for its medicines and technology; BeiGene's reliance on
third parties to conduct drug development, manufacturing,
commercialization, and other services; BeiGene’s limited experience
in obtaining regulatory approvals and commercializing
pharmaceutical products and its ability to obtain additional
funding for operations and to complete the development of its drug
candidates and achieve and maintain profitability; and those risks
more fully discussed in the section entitled “Risk Factors” in
BeiGene’s most recent quarterly report on Form 10-Q, as well as
discussions of potential risks, uncertainties, and other important
factors in BeiGene's subsequent filings with the U.S. Securities
and Exchange Commission. All information in this press release is
as of the date of this press release, and BeiGene undertakes no
duty to update such information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231109537270/en/
Investor Liza Heapes +1 857-302-5663 ir@beigene.com
Media Kyle Blankenship +1 667-351-5176
media@beigene.com
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Apr 2024 to May 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From May 2023 to May 2024